Study Evaluating Desvenlafaxine Succinate Sustained-release (DVS SR) in Adult Outpatients With Pain Associated With Diabetic Peripheral Neuropathy
NCT ID: NCT00283842
Last Updated: 2011-10-24
Study Results
Outcome measurements, participant flow, baseline characteristics, and adverse events have been published for this study.
View full resultsBasic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
TERMINATED
PHASE3
408 participants
INTERVENTIONAL
2006-03-31
2008-06-30
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
TREATMENT
TRIPLE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
desvenlafaxine succinate sustained-release (DVS SR) 50mg
DVS SR
desvenlafaxine succinate sustained-release (DVS SR) 100mg
DVS SR
desvenlafaxine succinate sustained-release (DVS SR) 200mg
DVS SR
desvenlafaxine succinate sustained-release (DVS SR) 400mg
DVS SR
Placebo
Placebo
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
DVS SR
Placebo
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Painful symptoms of diabetic neuropathy in the lower extremities extremities for at least 6 months
Exclusion Criteria
* Uncontrolled diabetes
18 Years
ALL
No
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
Wyeth is now a wholly owned subsidiary of Pfizer
INDUSTRY
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Medical Monitor
Role: STUDY_DIRECTOR
Wyeth is now a wholly owned subsidiary of Pfizer
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
Mesa, Arizona, United States
Peoria, Arizona, United States
Phoenix, Arizona, United States
Encino, California, United States
Newport Beach, California, United States
Walnut Creek, California, United States
Pueblo, Colorado, United States
New Britain, Connecticut, United States
Stratford, Connecticut, United States
Waterbury, Connecticut, United States
Fort Myers, Florida, United States
Palm Beach Gardens, Florida, United States
Pembroke Pines, Florida, United States
St. Petersburg, Florida, United States
West Palm Beach, Florida, United States
Lawrenceville, Georgia, United States
Roswell, Georgia, United States
Coeur d'Alene, Idaho, United States
Chicago, Illinois, United States
Evansville, Indiana, United States
Des Moines, Iowa, United States
Madisonville, Kentucky, United States
Springfield, Massachusetts, United States
Ann Arbor, Michigan, United States
Kansas City, Missouri, United States
St Louis, Missouri, United States
St Louis, Missouri, United States
Billings, Montana, United States
Omaha, Nebraska, United States
Albany, New York, United States
Flushing, New York, United States
New York, New York, United States
Rochester, New York, United States
Staten Island, New York, United States
Fargo, North Dakota, United States
Cincinnati, Ohio, United States
Dayton, Ohio, United States
Toledo, Ohio, United States
Collegeville, Pennsylvania, United States
Feasterville, Pennsylvania, United States
Harleysville, Pennsylvania, United States
Warwick, Rhode Island, United States
Austin, Texas, United States
Dallas, Texas, United States
San Antonio, Texas, United States
Midvale, Utah, United States
Salt Lake City, Utah, United States
Virginia Beach, Virginia, United States
Lakewood, Washington, United States
Tacoma, Washington, United States
Milwaukee, Wisconsin, United States
Countries
Review the countries where the study has at least one active or historical site.
References
Explore related publications, articles, or registry entries linked to this study.
Allen R, Sharma U, Barlas S. Clinical experience with desvenlafaxine in treatment of pain associated with diabetic peripheral neuropathy. J Pain Res. 2014 Jun 23;7:339-51. doi: 10.2147/JPR.S55682. eCollection 2014.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
3151A5-322
Identifier Type: -
Identifier Source: org_study_id